| Attributes | Values |
|---|
| rdf:type
| |
| http://linked.open...gbank/description
| - An organoplatinum compound that possesses antineoplastic activity. [PubChem] (en)
|
| http://linked.open...y/drugbank/dosage
| |
| http://linked.open...generalReferences
| - # Natarajan G, Malathi R, Holler E: Increased DNA-binding activity of cis-1,1-cyclobutanedicarboxylatodiammineplatinum(II) (carboplatin) in the presence of nucleophiles and human breast cancer MCF-7 cell cytoplasmic extracts: activation theory revisited. Biochem Pharmacol. 1999 Nov 15;58(10):1625-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10535754 # Knox RJ, Friedlos F, Lydall DA, Roberts JJ: Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA. Cancer Res. 1986 Apr;46(4 Pt 2):1972-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/3512077 # Canetta R, Rozencweig M, Carter SK: Carboplatin: the clinical spectrum to date. Cancer Treat Rev. 1985 Sep;12 Suppl A:125-36. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/3002623 (en)
|
| http://linked.open...gy/drugbank/group
| |
| http://linked.open...drugbank/halfLife
| - Initial plasma half-life (alpha) = 1.1 to 2 hours; Post distribution plasma half-life (beta) = 2.6 - 5.9 hours. (en)
|
| http://linked.open...ugbank/indication
| - For the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of PARAPLATIN and cyclophosphamide. It is also indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin. (en)
|
| http://linked.open...bank/manufacturer
| |
| sameAs
| |
| Title
| |
| adms:identifier
| |
| http://linked.open...mechanismOfAction
| - Alkylating agents work by three different mechanisms: 1) attachment of alkyl groups to DNA bases, resulting in the DNA being fragmented by repair enzymes in their attempts to replace the alkylated bases, preventing DNA synthesis and RNA transcription from the affected DNA, 2) DNA damage via the formation of cross-links (bonds between atoms in the DNA) which prevents DNA from being separated for synthesis or transcription, and 3) the induction of mispairing of the nucleotides leading to mutations. (en)
|
| http://linked.open...drugbank/packager
| |
| http://linked.open...outeOfElimination
| - The major route of elimination of carboplatin is renal excretion. After 24 hours, all of the platinum is recovered in the urine as carboplatin. Whether biliary excretion occurs is not known. (en)
|
| http://linked.open.../drugbank/synonym
| - Carboplatin (en)
- Paraplatin (en)
- cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II) (en)
- CBDCA (en)
- cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii) (en)
- cis-Diammine(1,1-cyclobutanedicarboxylato)platinum (en)
|
| http://linked.open...drugbank/toxicity
| - Toxic by ingestion. May be create toxic effect through inhalation or skin contact. May cause reproductive defects. May act as a sensitizer. ORL-RAT LD<sub>50</sub> 343 mg kg-1; SCN-RAT LD<sub>50</sub> 72 mg kg-1; IPN-MUS LD<sub>50</sub> 118 mg kg-1 (en)
|
| http://linked.open...umeOfDistribution
| - * 16 L [apparent volume of distribution, 30 minute IV infusion of 300 mg/m^2 to 500 mg/m^2] (en)
|
| http://linked.open.../drug/hasAHFSCode
| |
| http://linked.open...k/foodInteraction
| - Avoid echinacea as it may decrease effectiveness of immunosuppresants like carboplatin (en)
|
| http://linked.open...nk/proteinBinding
| - Carboplatin is not bound to plasma protein. However, the platinum itself from carboplatin irreversibly binds to plasma proteins and is slowly eliminated with a minimum half-life of 5 days. (en)
|
| http://linked.open...ynthesisReference
| - Jingzun Wang, Huisheng Qu, Lei Wang, Ting Wang, "Supermolecular carboplatin derivatives, their preparation and pharmaceutical composition containing them as active ingredient and applications of the compositions." U.S. Patent US07259270, issued August 21, 2007. (en)
|
| foaf:page
| |
| http://linked.open...ugbank/IUPAC-Name
| |
| http://linked.open...gy/drugbank/InChI
| |
| http://linked.open...Molecular-Formula
| |
| http://linked.open.../Molecular-Weight
| |
| http://linked.open...noisotopic-Weight
| |
| http://linked.open...y/drugbank/SMILES
| |
| http://linked.open...ogy/drugbank/logP
| |
| http://linked.open...l/drug/hasATCCode
| |
| http://linked.open...nd-Acceptor-Count
| |
| http://linked.open...-Bond-Donor-Count
| |
| http://linked.open...drugbank/InChIKey
| |
| http://linked.open...urface-Area--PSA-
| |
| http://linked.open...nk/Polarizability
| |
| http://linked.open...bank/Refractivity
| |
| http://linked.open...atable-Bond-Count
| |
| http://linked.open...ugbank/absorption
| - The Cmax values and areas under the plasma concentration versus time curves from 0 to infinity (AUC inf) increase linearly with dose, although the increase was slightly more than dose proportional. Carboplatin exhibits linear pharmacokinetics. (en)
|
| http://linked.open.../affectedOrganism
| - Humans and other mammals (en)
|
| http://linked.open...casRegistryNumber
| |
| http://linked.open...drugbank/category
| |
| http://linked.open...rugbank/clearance
| - * 4.4 L/hour [total body clearance, 30 minute IV infusion of 300 mg/m^2 to 500 mg/m^2] (en)
|
| http://linked.open...gbank/containedIn
| |
| http://linked.open...k/Bioavailability
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)